(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 May 2013 (23.05.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/074974 A3

(51) International Patent Classification:
C12N 15/11 (2006.01) *A61K 31/7125* (2006.01)
C12N 15/113 (2010.01) *A61K 31/713* (2006.01)

(21) International Application Number:
PCT/US2012/065601

(22) International Filing Date:
16 November 2012 (16.11.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/561,710 18 November 2011 (18.11.2011) US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.** [US/US]; 300 Third Street, Cambridge, MA 02142 (US).

(72) Inventors: **RAJEEV, Kallanthottathil, G.**; 300 Third Street, Cambridge, MA 02142 (US). **ZIMMERMANN, Tracy**; 300 Third Street, Cambridge, MA 02142 (US). **MANOHARAN, Muthiah**; 300 Third Street, Cambridge, MA 02142 (US). **MAIER, Martin**; 300 Third Street, Cambridge, MA 02142 (US). **KUCHIMANCHI, Satyanarayana**; Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, MA 02142 (US). **CHARISSE, Klaus**; Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, MA 02142 (US).

(74) Agent: **TOWNES, Jeffrey, N.**; LeClairRyan, 2318 Mill Road, Suite 1100, Alexandria, VA 22314 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
8 August 2013

WO 2013/074974 A3

(54) Title: MODIFIED RNAI AGENTS

(57) Abstract: One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene. The dsRNA duplex comprises one or more motifs of three identical modifications on three consecutive nucleotides in one or both strand, particularly at or near the cleavage site of the strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.